Skip to content

Breath Gas Analysis for the Diagnosis of Breast Cancer

Leistungsbewertungsprüfung: Atemluftanalyse für Die Diagnose Von Brustkrebs, für Die Überwachung Der Therapie Und für Die Voraussage Des Metastasenrisikos

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01105468
Enrollment
202
Registered
2010-04-16
Start date
2010-04-30
Completion date
2017-04-30
Last updated
2013-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mamma Carcinoma

Keywords

Breath gas analysis, Volatile components in exhaled breath

Brief summary

The volatile content of the exhaled breath gas of mamma carcinoma patients will be chemically analyzed by proton-transfer-reaction time of flight mass spectrometry. The goal of the study is to determine typical breath gas components that allow to distinguish patients with mamma carcinoma from women without carcinoma. Further, the investigators will test whether these breath gas markers can be used as tumor markers, which change in a typical manner during the progress of the disease. Finally the data will be investigated for the presence of marker components, that identify patients who will develop metastasis.

Interventions

DEVICEBreath Collecting Unit

Collect two breath gas samples per patient on one day before surgery

Sponsors

Medical University Innsbruck
CollaboratorOTHER
Ionimed Analytik GmbH
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* Mamma carcinoma diagnosed by histology (cases) * Mamma carcinoma excluded by radiology (controls) * At the time of diagnosis before surgery * At the beginning and during chemotherapy;

Exclusion criteria

* No informed consent form singed

Design outcomes

Primary

MeasureTime frameDescription
Breath gas markers3 yearsBreath gas markers that allow to distinguish patients with mamma carcinoma from women without carcinoma;

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026